Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Sonic (ASX:SHL) Share Price Rises 3% After Healthy FY19 Report

The Sonic Healthcare Limited (ASX:SHL) share price rose 3% in response to the healthy FY19 result. 

The Sonic Healthcare Limited (ASX: SHL) share price rose 3% in response to the healthy FY19 result.

Sonic Healthcare is one of Australia’s largest healthcare businesses, it provides laboratory services, pathology, and radiology services. It is actually the world’s third largest pathology/laboratory medicine company. It has operations in Australia, USA, Germany, Belgium, Switzerland, the United Kingdom, Ireland and New Zealand.

Sonic’s FY19 Result

The pathology business revealed revenue growth of 11.6% to $6.2 billion driven by organic revenue growth for the group of 4% on a constant currency basis.

The Australian, US and UK laboratory operations and the imaging division had higher growth rates whilst the German and Belgian operations were affected by regulatory changes.

Sonic said it achieved its guidance with underlying EBITDA growth of 6.7% (click here to learn what EBITDA means). EBITDA growth was 13.3% to $1.1 billion.

The healthcare company reported net profit after tax (NPAT) rose by 15.6% to $550 million. This compared to the market expectations of $533.33 million according to CommSec and Bloomberg, so it seems to have materially beaten expectations.

During the year Sonic acquired anatomical pathology company Aurora Diagnostics in the US for $750 million. It also decided to sell its 85% stake of German GLP Systems, returning $130 million of cash.

Sonic Healthcare Management Comments

Sonic CEO Dr Colin Goldschmidt said: “Sonic Healthcare has produced another solid financial result in the 2019 financial year, in line with our expectations.

Strategically we have taken major steps forward, opening up new pathways for future growth.”

Sonic Healthcare Dividend

The Sonic Healthcare Board declared a final dividend of $0.51 per share, which is an increase of 4.1%. That brings the full year dividend to $0.84 per share, an increase of 3.7% over last year.

Is Sonic Healthcare A Buy?

Sonic is valued at 23 times the estimated earnings for the 2020 financial year.

It’s a solid business with steadily growing earnings and a fully franked dividend yield of around 3%. It’s also exposed to the ageing population tailwinds. It could be part of a diversified defensive portfolio, but I prefer the idea of the reliable businesses in the free report below instead even more.

[ls_content_block id=”14945″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content